Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

@article{Zhang2016GemcitabinePC,
  title={Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.},
  author={Li Zhang and Yan Huang and Shaodong Hong and Yunpeng Yang and Gengsheng Yu and Jun Jia and Peijian Peng and Xuan Wu and Qing Lin and Xuping Xi and Jiewen Peng and Mingjun Xu and Dongping Chen and Xiaojun Lu and Ren-sheng Wang and Xiaolong Cao and Xiaozhong Chen and Zhixiong Lin and Jianping Xiong and Qin Lin and Conghua Xie and Zhihua Li and Jianji Pan and Jingao Li and Shixiu Wu and Yingni Lian and Quanlie Yang and Chong Zhao},
  journal={Lancet},
  year={2016},
  volume={388 10054},
  pages={1883-1892}
}
BACKGROUND Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. METHODS In this… CONTINUE READING